Jeak Ling Ding

Title: **Jeak Ling Ding: Innovator in Endotoxin Neutralization**

Introduction

Jeak Ling Ding is a notable inventor based in Singapore, recognized for his significant contributions to the field of biomedical innovation. With an impressive portfolio of ten patents, his work primarily focuses on developing therapies for gram-negative bacterial infections, with particular emphasis on endotoxin-neutralizing agents.

Latest Patents

One of Jeak Ling Ding's latest patents involves the development of Factor C for treating gram-negative bacterial infections. This innovation discloses recombinant fragments of Factor C, which exhibit remarkable potency in recognizing, binding to, neutralizing, and removing endotoxin. These molecules have potential applications in anti-microbial, anti-endotoxin, and anti-sepsis therapies. His research highlights the SSCrFCES protein, a 38 kDa protein representing the LPS-binding domain of Factor C. This protein has shown superior binding affinity for endotoxin, confirmed through both ELISA-based assays and surface plasmon resonance. Noteworthy findings indicate that the 50% endotoxin-neutralizing concentration of SSCrFCES is 0.069 µM against 200 EU of endotoxin, making it a formidable inhibitor of the LAL coagulation cascade. Despite partial attenuation by human serum, SSCrFCES demonstrates a potent ability to inhibit LPS-induced secretion of hTNF-α and hIL-8 by THP-1 cells, surpassing the efficacy of polymyxin B. Furthermore, SSCrFCES has proven non-cytotoxic with a clearance rate of 4.7 ml/minute, indicating its potential for treating endotoxin-induced septic shock.

Another aspect of his patent applications includes the innovative use of sushi peptides and their mutant derivatives as potent antimicrobials. Chemically synthesized S3 peptide, derived from the Sushi3 domain of Factor C, effectively binds and neutralizes LPS activity. The study showcases the construction and expression of tandem multimers of the S3 gene, which facilitates large-scale production and enhances their inhibitory effect on LPS-induced activities.

Career Highlights

Jeak Ling Ding is affiliated with the National University of Singapore, where he conducts cutting-edge research in the area of endotoxin neutralization. His contributions have been pivotal in advancing our understanding and treatment of gram-negative bacterial infections.

Collaborations

Throughout his career, Jeak has collaborated with esteemed colleagues, such as BoW Ho and Nguan Soon Tan. Their combined expertise has further strengthened the research outcomes and innovation potential of their projects.

Conclusion

Jeak Ling Ding exemplifies the spirit of innovation in the biomedical field with his pioneering work on endotoxin-neutralizing agents. His patents not only address critical health challenges associated with gram-negative bacterial infections but also open new avenues for therapeutic advancements. As he continues his work at the National University of Singapore, his contributions are expected to have significant impacts on global health.